# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2021 Earnings Results

**Report date:** 2021-05-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2021

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.37%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.89 | N/A | +27.12% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the strong EPS results, highlighting their commitment to innovation. They emphasized the importance of maintaining access to their products for patients.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on advancing our pipeline and ensuring patient access to our therapies.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Regeneron's strong EPS performance, exceeding expectations by over 27%, has positively impacted investor sentiment, resulting in a 3.37% increase in stock price. The company did not provide revenue figures or guidance, leaving some uncertainty for investors. However, the focus on advancing their product pipeline suggests potential for future growth.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2021_